CY1123251T1 - Μεθοδοι για την αγωγη dlbcl - Google Patents

Μεθοδοι για την αγωγη dlbcl

Info

Publication number
CY1123251T1
CY1123251T1 CY20201100425T CY201100425T CY1123251T1 CY 1123251 T1 CY1123251 T1 CY 1123251T1 CY 20201100425 T CY20201100425 T CY 20201100425T CY 201100425 T CY201100425 T CY 201100425T CY 1123251 T1 CY1123251 T1 CY 1123251T1
Authority
CY
Cyprus
Prior art keywords
methods
dlbcl
treatment
specifically
binding portion
Prior art date
Application number
CY20201100425T
Other languages
English (en)
Inventor
Gerhard Zugmaier
Dirk Nagorsen
Juergen Scheele
Original Assignee
Amgen Research (Munich) Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45023802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1123251(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Research (Munich) Gmbh filed Critical Amgen Research (Munich) Gmbh
Publication of CY1123251T1 publication Critical patent/CY1123251T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Carbon And Carbon Compounds (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μέσα και μεθόδους για την αγωγή του διάχυτου λεμφώματος από μεγάλα Β κύτταρα (DLBCL). Συγκεκριμένα, ένα διειδικό αντίσωμα CD19 x CD3 το οποίο στρατολογεί Τ κύτταρα μέσω του τμήματος δέσμευσης του CD3 και ταυτόχρονα δεσμεύεται στο CD 19 στην επιφάνεια, συγκεκριμένα, κυττάρων λεμσώματος μέσω του τμήματος δέσμευσης του CD 19 (δηλαδή, ένα διειδικό αντίσωμα στρατολόγησης Τ κυττάρων, «ΒiΤΕ») χορηγείται για χρήση στην αγωγή καρκινικής μάζας δικτυολεμφοκυτταρικού ιστού ή/και εξωαδενικού λεμφώματος που προκαλείται από DLBCL σε έναν ασθενή.
CY20201100425T 2010-10-27 2020-05-08 Μεθοδοι για την αγωγη dlbcl CY1123251T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40710710P 2010-10-27 2010-10-27
PCT/EP2011/068851 WO2012055961A1 (en) 2010-10-27 2011-10-27 Means and methods for treating dlbcl
EP15195076.3A EP3018145B1 (en) 2010-10-27 2011-10-27 Means and methods for treating dlbcl
EP11787633.4A EP2632954B2 (en) 2010-10-27 2011-10-27 Means and methods for treating dlbcl

Publications (1)

Publication Number Publication Date
CY1123251T1 true CY1123251T1 (el) 2021-10-29

Family

ID=45023802

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20161100083T CY1117155T1 (el) 2010-10-27 2016-01-29 Μεσα και μεθοδοι για θεραπευτικη αγωγη dlbcl
CY20181100508T CY1120227T1 (el) 2010-10-27 2018-05-16 Μεσα και μεθοδοι για την αγωγη dlbcl
CY20201100425T CY1123251T1 (el) 2010-10-27 2020-05-08 Μεθοδοι για την αγωγη dlbcl

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20161100083T CY1117155T1 (el) 2010-10-27 2016-01-29 Μεσα και μεθοδοι για θεραπευτικη αγωγη dlbcl
CY20181100508T CY1120227T1 (el) 2010-10-27 2018-05-16 Μεσα και μεθοδοι για την αγωγη dlbcl

Country Status (31)

Country Link
US (2) US9192665B2 (el)
EP (3) EP3018145B1 (el)
JP (3) JP5997168B2 (el)
KR (1) KR101889995B1 (el)
CN (2) CN105251003B (el)
AU (1) AU2011322581B2 (el)
CA (1) CA2815119C (el)
CL (1) CL2013001138A1 (el)
CR (1) CR20130245A (el)
CY (3) CY1117155T1 (el)
DK (3) DK2632954T4 (el)
EA (1) EA032139B1 (el)
ES (3) ES2787044T3 (el)
HK (1) HK1188229A1 (el)
HR (2) HRP20151444T4 (el)
HU (3) HUE048639T2 (el)
IL (3) IL225924A (el)
LT (2) LT3018145T (el)
MA (1) MA34619B1 (el)
ME (1) ME02311B (el)
MY (1) MY163057A (el)
NZ (2) NZ609201A (el)
PL (3) PL2632954T5 (el)
PT (3) PT3412687T (el)
RS (3) RS57260B1 (el)
SG (1) SG189869A1 (el)
SI (3) SI2632954T2 (el)
SM (1) SMT201600050B (el)
TR (1) TR201808019T4 (el)
UA (1) UA111175C2 (el)
WO (1) WO2012055961A1 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1874821B1 (de) 2005-04-26 2013-04-17 Trion Pharma Gmbh Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
SI2632954T2 (sl) * 2010-10-27 2021-11-30 Amgen Research (Munich) Gmbh Sredstva in postopki za zdravljenje dlbcl
US10130638B2 (en) * 2010-11-10 2018-11-20 Amgen Research (Munich) Gmbh Prevention of adverse effects caused by CD3 specific binding domains
JO3529B1 (ar) * 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
WO2015057834A1 (en) * 2013-10-15 2015-04-23 The California Institute For Biomedical Research Peptidic chimeric antigen receptor t cell switches and uses thereof
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
EP3298033B2 (en) 2015-05-18 2023-07-12 TCR2 Therapeutics Inc. Compositions and medical uses for tcr reprogramming using fusion proteins
JP2019532017A (ja) * 2016-07-14 2019-11-07 フレッド ハッチンソン キャンサー リサーチ センター がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物
EP3494138A1 (en) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
DK3445787T3 (da) 2016-10-07 2021-03-01 Tcr2 Therapeutics Inc Sammensætninger og fremgangsmåder til omprogrammering af t-cellereceptorer under anvendelse af fusionsproteiner
CN110267982B (zh) 2016-10-19 2024-02-23 斯克利普斯研究所 具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途
AU2017363311A1 (en) 2016-11-22 2019-06-13 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
WO2020099513A1 (en) * 2018-11-13 2020-05-22 Lipoxen Technologies Limited Glycopolysialylation of blinatumomab
BR112021021996A2 (pt) * 2019-05-03 2022-01-11 Kite Pharma Inc Métodos para administração de imunoterapia com receptores de antígeno quimérico
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
KR20230131464A (ko) * 2020-12-04 2023-09-13 모르포시스 아게 항-cd19 병용 요법
KR20230157315A (ko) 2021-01-28 2023-11-16 리제너론 파마슈티칼스 인코포레이티드 사이토카인 방출 증후군을 치료하기 위한 조성물 및 방법
US20230357446A1 (en) 2022-04-11 2023-11-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
NZ507381A (en) 1998-04-21 2003-12-19 Micromet Ag CD19xCD3 specific polypeptides and uses thereof
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
SI1691833T1 (sl) 2003-11-28 2010-06-30 Micromet Ag Zmes s polipeptidi
CN105535967B (zh) 2005-02-15 2022-05-03 杜克大学 抗cd19抗体及其在肿瘤学中的应用
EP1874821B1 (de) * 2005-04-26 2013-04-17 Trion Pharma Gmbh Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
CN101331151A (zh) * 2005-12-16 2008-12-24 麦克罗梅特股份公司 治疗肿瘤性疾病的方式和方法
AU2006326727A1 (en) * 2005-12-16 2007-06-21 Amgen Research (Munich) Gmbh Means and methods for the treatment of tumorous diseases
EP2066349B1 (en) 2006-09-08 2012-03-28 MedImmune, LLC Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases
BRPI0809594A2 (pt) 2007-04-03 2019-08-27 Micromet Ag polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s)
ME02363B (me) * 2008-11-07 2016-06-20 Amgen Res Munich Gmbh Liječenje akutne limfoblastične leukemije
RS54655B2 (sr) 2009-10-27 2021-04-29 Amgen Res Munich Gmbh Dozni režim za primenu cd19xcd3 bispecifičnog antitela
SI2632954T2 (sl) * 2010-10-27 2021-11-30 Amgen Research (Munich) Gmbh Sredstva in postopki za zdravljenje dlbcl

Also Published As

Publication number Publication date
PL3412687T3 (pl) 2020-07-27
CR20130245A (es) 2013-09-20
CN103459425B (zh) 2015-11-25
NZ719768A (en) 2021-07-30
PT2632954E (pt) 2016-02-03
EP2632954B1 (en) 2015-11-25
HUE048639T2 (hu) 2020-08-28
JP5997168B2 (ja) 2016-09-28
CA2815119C (en) 2023-01-10
HK1188229A1 (en) 2014-04-25
UA111175C2 (uk) 2016-04-11
CL2013001138A1 (es) 2014-11-14
ES2563439T3 (es) 2016-03-15
EA201390387A1 (ru) 2013-10-30
US20160208001A1 (en) 2016-07-21
US9192665B2 (en) 2015-11-24
US20130287778A1 (en) 2013-10-31
JP6522722B2 (ja) 2019-05-29
SI3018145T1 (en) 2018-08-31
RS60094B1 (sr) 2020-05-29
SI2632954T2 (sl) 2021-11-30
DK2632954T3 (en) 2016-02-01
IL225924A0 (en) 2013-06-27
KR101889995B1 (ko) 2018-08-20
CY1120227T1 (el) 2018-12-12
IL260774B (en) 2019-02-28
CY1117155T1 (el) 2017-04-05
RS54525B1 (en) 2016-06-30
RS57260B1 (sr) 2018-08-31
MA34619B1 (fr) 2013-10-02
JP2016164192A (ja) 2016-09-08
IL225924A (en) 2017-12-31
SG189869A1 (en) 2013-06-28
SMT201600050B (it) 2016-04-29
CN105251003B (zh) 2019-08-02
CA2815119A1 (en) 2012-05-03
LT3018145T (lt) 2018-05-10
IL256110A (en) 2018-02-28
PT3412687T (pt) 2020-04-03
EP3018145B1 (en) 2018-04-04
PL2632954T5 (pl) 2021-11-02
AU2011322581A1 (en) 2013-05-09
NZ701715A (en) 2016-05-27
PL3018145T3 (pl) 2018-09-28
NZ609201A (en) 2015-01-30
PL2632954T3 (pl) 2016-05-31
PT3018145T (pt) 2018-05-17
EP3018145A1 (en) 2016-05-11
HRP20180882T1 (hr) 2018-07-27
EP3412687B1 (en) 2020-03-18
IL256110B (en) 2018-08-30
HUE037786T2 (hu) 2018-09-28
SI2632954T1 (sl) 2016-02-29
JP2018039838A (ja) 2018-03-15
HRP20151444T4 (hr) 2021-08-20
EA032139B1 (ru) 2019-04-30
ES2787044T3 (es) 2020-10-14
JP2013540799A (ja) 2013-11-07
DK2632954T4 (da) 2021-08-09
RS54525B2 (sr) 2021-08-31
DK3412687T3 (da) 2020-05-11
MY163057A (en) 2017-08-15
HUE027678T2 (en) 2016-11-28
WO2012055961A1 (en) 2012-05-03
ES2563439T5 (es) 2022-02-04
KR20140019298A (ko) 2014-02-14
DK3018145T3 (en) 2018-05-28
US10696744B2 (en) 2020-06-30
ES2675299T3 (es) 2018-07-10
HRP20151444T1 (hr) 2016-01-29
TR201808019T4 (tr) 2018-06-21
EP2632954A1 (en) 2013-09-04
ME02311B (me) 2016-06-20
CN105251003A (zh) 2016-01-20
SI3412687T1 (sl) 2020-07-31
AU2011322581B2 (en) 2015-04-23
EP2632954B2 (en) 2021-07-07
EP3412687A1 (en) 2018-12-12
LT3412687T (lt) 2020-07-27
JP6254220B2 (ja) 2017-12-27
CN103459425A (zh) 2013-12-18

Similar Documents

Publication Publication Date Title
CY1123251T1 (el) Μεθοδοι για την αγωγη dlbcl
CY1124634T1 (el) Μορια προσδεσης pd-1 και lag-3 και μεθοδοι χρησης αυτων
CY1119551T1 (el) Αντισωματα τα οποια δεσμευουν κυτταρο-συνδεδεμενο ca 125/0722ρ και μεθοδοι χρησης αυτων
CY1119994T1 (el) Συνθεσεις και μεθοδοι για αυξηση της μυϊκης μαζας και της μυϊκης δυναμης ανταγωνιζοντας ειδικα ton gdf8 και/ή την ακτιβινη α
CY1120664T1 (el) Χρησεις και συνθεσεις για αντιμετωπιση διαπυητικης ιδρωταδενιτιδας (δι)
CY1120119T1 (el) Προβιοτικες θεραπειες για αυτισμο
CY1113984T1 (el) Προϊοντα συζευξης μεϋτανσινοειδους dm1 με αντισωμα trastuzumab, συνδεδεμενα μεσω μη-διασπασιμου συνδετηρα και χρηση αυτων στη θεραπεια ογκων
CY1119353T1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
CY1118710T1 (el) Συνθεσεις για την θεραπεια της πολλαπλης σκληρυνσης
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
CL2007003622A1 (es) Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
CY1113190T1 (el) Μεθοδος αγωγης της αιμολυτικης νοσου
UY34077A (es) Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b
CY1118223T1 (el) Μεθοδοι θεραπειας του διαβητη με ανταγωνιστες toy dll4
CY1119890T1 (el) Θεραπευτικη αγωγη ογκων χρησιμοποιωντας ειδικο αντισωμα αντι-l1
EA201301072A1 (ru) Антитела против il-23p19 и их применение
UA116618C2 (uk) СКОНСТРУЙОВАНЕ НА ОСНОВІ ЦИСТЕЇНУ АНТИТІЛО ПРОТИ CD79b
EA201071068A1 (ru) Антитела к tyrp1
TR201904882T4 (tr) Tıbbi kullanım için bispesifik antikorlar.
AR086984A1 (es) Anticuerpo anti-cxcr4 con funciones efectoras y su uso en el tratamiento del cancer
BRPI0407680A (pt) métodos para diagnóstico de cáncer e diminuição de metástase por células cancerosas
BR112023004296A2 (pt) Método para tratar linfoma de célula b grande difusa em um indivíduo humano
CY1124082T1 (el) Μεθοδοι θεραπειας με χρηση κινητοποιητων βλαστικων κυτταρων και ανοσοκατασταλτικων παραγοντων
CY1111328T1 (el) Χαρακτηρισμος: αξομαδολη για τη θεραπεια πονου σε αρθριτιδα
RU2011129048A (ru) Способ прогнозирования эффективности терапии преэклампсии